Michael M. Abecassis - 25 Apr 2025 Form 4 Insider Report for PharmaCyte Biotech, Inc. (PMCB)

Role
Director
Signature
/s/ Michael M. Abecassis
Issuer symbol
PMCB
Transactions as of
25 Apr 2025
Transactions value $
-$17,213
Form type
4
Filing time
12 Dec 2025, 17:06:55 UTC
Previous filing
17 Jul 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Abecassis Michael M Director C/O PHARMACYTE BIOTECH, INC., 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS /s/ Michael M. Abecassis 12 Dec 2025 0001879281

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PMCB Common Stock Award $0 +37.5K +2249.55% $0.00 39.2K 12 Dec 2025 Direct
transaction PMCB Common Stock Tax liability -$17.2K -16.9K -43.08% $1.02 22.3K 12 Dec 2025 Direct F1
holding PMCB Common Stock 800 25 Apr 2025 By Transplant Consulting LLC

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PMCB Stock Option (Right to Buy) Award $0 +63.2K $0.00 63.2K 25 Apr 2025 Common Stock 63.2K $1.22 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction.
F2 The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Abecassis. This transaction is late due to an inadvertent administrative error and not any error of Mr. Abecassis.